...
enta-img

Enanta Pharmaceuticals Inc, Common Stock

ENTA

NSQ

$5.85

-$0.28

(-4.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$129.92M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
648.22K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.57
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.7 L
$17.8 H
$5.85

About Enanta Pharmaceuticals Inc, Common Stock

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameENTASectorS&P500
1-Week Return-16.43%-2.06%-0.55%
1-Month Return-38.87%-1.92%2.72%
3-Month Return-48.64%-10.4%7.66%
6-Month Return-50.55%-4.6%10.15%
1-Year Return-34.56%4.06%27.53%
3-Year Return-92.59%1.94%32.31%
5-Year Return-90.87%36.48%89.2%
10-Year Return-86.97%97.46%194.59%

Financials

Sep '20Sep '21Sep '22Sep '23Sep '245YR TREND
Total Revenue122.47M97.07M86.16M79.20M67.64M[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":79.26,"profit":true},{"date":"2022-09-30","value":70.35,"profit":true},{"date":"2023-09-30","value":64.67,"profit":true},{"date":"2024-09-30","value":55.22,"profit":true}]
Cost of Revenue--2.97M2.37M-[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":79.75,"profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Profit122.47M97.07M83.19M79.20M67.64M[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":79.26,"profit":true},{"date":"2022-09-30","value":67.92,"profit":true},{"date":"2023-09-30","value":64.67,"profit":true},{"date":"2024-09-30","value":55.22,"profit":true}]
Gross Margin100.00%100.00%96.55%100.00%100.00%[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":96.55,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Operating Expenses164.11M206.65M210.00M216.41M189.33M[{"date":"2020-09-30","value":75.83,"profit":true},{"date":"2021-09-30","value":95.49,"profit":true},{"date":"2022-09-30","value":97.04,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":87.48,"profit":true}]
Operating Income(41.64M)(109.57M)(123.84M)(137.21M)(121.69M)[{"date":"2020-09-30","value":-4163900000,"profit":false},{"date":"2021-09-30","value":-10957300000,"profit":false},{"date":"2022-09-30","value":-12384400000,"profit":false},{"date":"2023-09-30","value":-13720700000,"profit":false},{"date":"2024-09-30","value":-12169100000,"profit":false}]
Total Non-Operating Income/Expense13.09M4.01M3.23M12.42M-[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":30.67,"profit":true},{"date":"2022-09-30","value":24.67,"profit":true},{"date":"2023-09-30","value":94.9,"profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Pre-Tax Income(35.02M)(107.58M)(122.19M)(131.00M)(117.79M)[{"date":"2020-09-30","value":-3501900000,"profit":false},{"date":"2021-09-30","value":-10757900000,"profit":false},{"date":"2022-09-30","value":-12218800000,"profit":false},{"date":"2023-09-30","value":-13099500000,"profit":false},{"date":"2024-09-30","value":-11778800000,"profit":false}]
Income Taxes1.15M(28.58M)(433.00K)2.82M(1.74M)[{"date":"2020-09-30","value":40.73,"profit":true},{"date":"2021-09-30","value":-1013.22,"profit":false},{"date":"2022-09-30","value":-15.35,"profit":false},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":-61.79,"profit":false}]
Income After Taxes(36.17M)(79.00M)(121.75M)(133.82M)-[{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":"-","profit":true}]
Income From Continuous Operations(36.17M)(79.00M)(121.75M)(133.82M)-[{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(36.17M)(79.00M)(121.75M)(133.82M)(116.05M)[{"date":"2020-09-30","value":-3616800000,"profit":false},{"date":"2021-09-30","value":-7899600000,"profit":false},{"date":"2022-09-30","value":-12175500000,"profit":false},{"date":"2023-09-30","value":-13381600000,"profit":false},{"date":"2024-09-30","value":-11604500000,"profit":false}]
EPS (Diluted)(1.82)(3.91)(5.91)(6.37)(5.48)[{"date":"2020-09-30","value":-182,"profit":false},{"date":"2021-09-30","value":-391,"profit":false},{"date":"2022-09-30","value":-591,"profit":false},{"date":"2023-09-30","value":-637,"profit":false},{"date":"2024-09-30","value":-548,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ENTA
Cash Ratio 4.31
Current Ratio 5.21

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ENTA
ROA (LTM) -17.18%
ROE (LTM) -59.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ENTA
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ENTA
Trailing PE NM
Forward PE NM
P/S (TTM) 1.81
P/B 1.04
Price/FCF NM
EV/R 0.83
EV/Ebitda NM
PEG NM

FAQs

What is Enanta Pharmaceuticals Inc share price today?

Enanta Pharmaceuticals Inc (ENTA) share price today is $5.85

Can Indians buy Enanta Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Enanta Pharmaceuticals Inc (ENTA) on Vested. To buy Enanta Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Enanta Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Enanta Pharmaceuticals Inc (ENTA) via the Vested app. You can start investing in Enanta Pharmaceuticals Inc (ENTA) with a minimum investment of $1.

How to invest in Enanta Pharmaceuticals Inc shares from India?

You can invest in shares of Enanta Pharmaceuticals Inc (ENTA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ENTA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Enanta Pharmaceuticals Inc shares
What is Enanta Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Enanta Pharmaceuticals Inc (ENTA) is $17.8. The 52-week low price of Enanta Pharmaceuticals Inc (ENTA) is $5.7.

What is Enanta Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Enanta Pharmaceuticals Inc (ENTA) is

What is Enanta Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Enanta Pharmaceuticals Inc (ENTA) is 1.04

What is Enanta Pharmaceuticals Inc dividend yield?

The dividend yield of Enanta Pharmaceuticals Inc (ENTA) is 0.00%

What is the Market Cap of Enanta Pharmaceuticals Inc?

The market capitalization of Enanta Pharmaceuticals Inc (ENTA) is $129.92M

What is Enanta Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Enanta Pharmaceuticals Inc is ENTA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top